In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

Proactive steps like strengthening defenses, securing critical assets, implementing monitoring systems, and collaborating ...

This trial is anticipated to be a single-cycle trial in approximately 36 patients with a pathologic response rate as the primary endpoint ... with an immune checkpoint inhibitor in squamous cell head ...